# Vensun Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vensun-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.vensunrx.com
- Total disclosed funding: $44M
- Latest round: Series C (Dec 1, 2016)
- Investors on record: 3

## About

Vensun Pharmaceuticals, Inc. is a U.S.-based company focused on developing and distributing a wide range of generic pharmaceutical prescription drugs, ensuring affordable access to essential medications for healthcare providers and patients.Founded in 2011, Vensun Pharmaceuticals, Inc. specializes in the development and distribution of generic pharmaceutical products. The company has successfully raised USD 22.5 mn in its Series C financing round led by Perceptive Advisors, with participation from Deerfield Management and JW Asset Management. Vensun is headquartered in the United States and has completed a total of six deals, with its most recent funding round occurring on December 1, 2016. The CEO of Vensun is Hemanshu Pandya.Vensun Pharmaceuticals, Inc. specializes in developing and distributing a diverse range of generic pharmaceutical prescription drugs. The company’s portfolio includes various dosage forms targeting multiple therapeutic categories, such as cardiovascular, infectious diseases, and chronic conditions. Vensun holds exclusive distribution rights for eight approved Abbreviated New Drug Application (ANDA) products and has over fifteen ANDA products pending FDA approval. Their products are developed in collaboration with partners to meet the needs of healthcare providers and patients requiring affordable medications, primarily serving markets across the United States.Vensun Pharmaceuticals generates revenue through distributing its generic prescription drugs to healthcare entities, including pharmacies, hospitals, and wholesalers. The company operates on a business-to-business model, forming partnerships and agreements with distributors and retailers to sell its pharmaceutical products. The revenue structure typically involves transactional agreements where clients place orders for products, fulfilled at agreed-upon prices, reflecting competitive pricing strategies prevalent in the generic pharmaceutical sector. Vensun's revenue potential is further supported by its pursuit of in-licensing opportunities and marketing of partner-developed products.Vensun Pharmaceuticals plans to leverage the funds from its Series C financing, amounting to USD 22.5 mn, to support the development and launch of new products, including over fifteen ANDA products awaiting FDA approval. The company aims to expand its market presence, focusing on increasing its distribution capabilities across the United States and potentially exploring new geographic regions. These initiatives are part of Vensun's strategy to enhance its product offerings and expand access to essential medications for patients.

## Funding rounds

- Series C, Dec 1, 2016, $23M — JW Asset Management, Deerfield Management, Perceptive Advisors
- Series B, Dec 19, 2013, $5.1M — JW Asset Management
- Series B, Oct 15, 2013, $11M — JW Asset Management
- Series A, Mar 27, 2012, $5.7M — JW Asset Management

## Investors

- JW Asset Management (https://capitalatlas.ai/funds/jw-asset-management) — Series A, Series B, Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C